Episode 045: Myeloma Series, Pt.6- Myeloma Treatment in Transplant Ineligible Patients
The Fellow on Call: The Heme/Onc Podcast
00:00
The Importance of Post-Protocol Therapy in Myeloma
10% overall survival gain at three years is a huge deal. The other thing we looked at was how many of these patients are M.R.D. negative? And this is just saying they have tiny, tiny amounts of disease left over. So that's also a huge 14%. That's a really good number for these patients. It sounds amazing. Great overall survival benefit, great M.R.'s negativity. What we should do in the United States is this DARA RD and dexamethasone revolve mid-stage trial will be approved soon. We don't know why it worked, but we think it did.
Transcript
Play full episode
